Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related ...

Imagine if losing weight were as simple as swallowing a daily pill-no needles, no injections and no anxiety. If you're among ...

GLP-1 medicines cause malnutrition in 22% of patients. Multivitamins are often inadequate. Patients need dietitian support ...

The Chinese biotech evaluated three different once-daily doses of its oral GLP-1 agonist, dubbed ASC30, in a phase 2 study of ...

At this year’s meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Eli Lilly sought to bolster the case for its oral GLP-1 orforglipron, showcasing more of the drug's ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today positive topline results in its 13-week Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared ...

On the heels of striking a deal with the Trump administration to reduce the prices of several of its most popular drugs for U.S. patients, Eli Lilly has unveiled additional savings for cash-paying ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. For the first time, a generic GLP-1 has been approved by ...

Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...

News and commentary from the endocrinology world ...